Orphan Drug Development for Rare Diseases: Therapeutic Challenges, Translational Strategies, and Global Health Equity

Abstract

Orphan drug development for rare diseases presents unique challenges that require targeted scientific, economic, and policy-based responses. With over 300 million individuals globally affected by rare diseases, the need for effective therapies is urgent. However, development is hindered by limited biological understanding, small patient populations, and difficulties in clinical trial recruitment. High research and development costs and inconsistent market incentives further discourage investment, especially in low- and middle-income countries (LMICs). Ethical concerns around access and affordability deepen disparities. To address these issues, legislative measures such as the U.S. Orphan Drug Act and similar policies in the EU and Japan offer benefits like market exclusivity and expedited regulatory review. Advances in genomic sequencing, artificial intelligence, and real-world data are enhancing diagnostics and drug discovery. Collaborative research models, adaptive trial designs, and decentralized clinical trials improve feasibility and inclusivity. Equity-driven frameworks such as tiered pricing and support for local manufacturing are critical to expanding access in LMICs.This article examines the interconnected challenges of orphan drug development and outlines evidence-based strategies to improve therapeutic innovation and global access. A coordinated, multisectoral effort is essential to ensure that the benefits of precision medicine and translational research extend beyond high-income countries and contribute to global health equity.